Government Caps Trade Margins on 137 Cancer Drugs at 30%
Starting November 9, a new regulation will limit the trade margins on cancer medications, potentially reducing prices significantly for patients.
The trade margin on 137 cancer drugs will be capped at 30% of MRP, effective November 9.
Patients could save approximately ₹2,500 crore annually due to this regulation.
The National Pharmaceutical Pricing Authority expects price reductions of up to 70% for these medications.
The Indian government has announced a significant regulatory change regarding the pricing of cancer medications. Effective November 9, the trade margin for 137 cancer drugs will be capped at 30% of the maximum retail price (MRP), a move aimed at making these essential drugs more affordable for patients. This decision comes as part of an emergency measure invoked by the government, which seeks to control the costs associated with cancer treatment amidst rising healthcare expenses.
The National Pharmaceutical Pricing Authority (NPPA) implemented this cap following a recommendation from an expert committee formed under the Directorate General of Health Services. This committee, established on October 9, included oncologists and health officials who identified the specific drugs to be regulated. The government has indicated that the list will encompass all cancer treatment drugs, excluding those already priced affordably. The NPPA anticipates that the new pricing structure could lead to a price drop of up to 70%, depending on the existing margins of each drug.
In a statement to the Supreme Court, Aishwarya Bhati, representing the government, projected annual savings for patients at around ₹2,500 crore. The NPPA's decision stems from concerns raised during court hearings about the exorbitant mark-ups on cancer drugs, which have been reported to range from 170% to over 700%. The Supreme Court has emphasized the need for urgent regulation of life-saving medications, prompting this intervention.
The cap will apply to both branded and generic drugs, whether imported or manufactured in India. Manufacturers have been given a week from the notification date to report revised prices to the NPPA. Hospitals and chemists will be required to charge these new prices and display them prominently, with state drug controllers responsible for enforcement. This regulatory change is expected to have a significant impact on the healthcare landscape, particularly for cancer patients who often face high treatment costs.
Looking ahead, the NPPA will continuously monitor the situation and may update the list of drugs subject to this cap based on market conditions and public health needs. The Supreme Court is scheduled to reconvene on October 27 to further discuss the implications of this regulation, as the government aims to ensure that patients receive necessary treatments without facing prohibitive costs.
